Literature DB >> 15659000

Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand.

B Janchawee1, W Wongpoowarak, T Owatranporn, V Chongsuvivatwong.   

Abstract

BACKGROUND: Drug-drug interaction is a potential cause of adverse drug reactions. The incidence of such drug interactions in university hospitals in Thailand is unknown.
PURPOSE: To estimate the rate of potential drug-drug interactions in outpatients of a typical Thai university hospital, and to identify risk factors for such interactions in Thai patients.
METHODS: One-year outpatients' prescription data were retrieved from the hospital computer records. Potential drug interactions were identified using the existing drug-interaction database system. Potential interactions within a specific prescription and involving drugs prescribed 1-, 3- and 7-day earlier were searched for. Possible associations between occurrence of an interaction and a patient's age and gender and the number of items on the prescription were explored.
RESULTS: The overall rate of potential drug interactions was 27.9% with a maximal value of 57.8% at the Department of Psychiatry. The rate of the most potentially significant interactions was 2.6%, being the highest in the Department of Medicine (6.0%), with isoniazid vs. rifampin as the most common interacting combination. The rate increased with the patient's age and prescription size (P=0.000). The odd's ratio of having at least one potential drug interaction was 1.8 (64.2%) when age increased by 20 years (P=0.000) and 2.8 (165.7%) when another drug was added (P=0.000). The rate of potential drug interactions was the same for both genders. The rate of potential drug interactions detected across prescriptions was higher than within prescriptions and was dependent on the time interval between prescriptions.
CONCLUSIONS: Potential drug interactions were common in our sample of patients. The rate of such interactions increased with the number of drugs prescribed and the patient's age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659000     DOI: 10.1111/j.1365-2710.2004.00598.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  26 in total

1.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

2.  A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Authors:  Johan Holm; Birgit Eiermann; Erik Eliasson; Buster Mannheimer
Journal:  Eur J Clin Pharmacol       Date:  2014-09-06       Impact factor: 2.953

3.  Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study.

Authors:  Cristiano Moura; Nília Prado; Francisco Acurcio
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system.

Authors:  Thilo Bertsche; Johannes Pfaff; Petra Schiller; Jens Kaltschmidt; Markus G Pruszydlo; Wolfgang Stremmel; Ingeborg Walter-Sack; Walter E Haefeli; Jens Encke
Journal:  Intensive Care Med       Date:  2010-02-09       Impact factor: 17.440

5.  Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study.

Authors:  Meng-Ting Wang; Chen-Yi Su; Agnes L F Chan; Pei-Wen Lian; Hsin-Bang Leu; Yu-Juei Hsu
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

6.  Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study.

Authors:  Chen-Fang Lin; Chun-Yu Wang; Chyi-Huey Bai
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923

Review 7.  Introducing the Big Knowledge to Use (BK2U) challenge.

Authors:  Yehoshua Perl; James Geller; Michael Halper; Christopher Ochs; Ling Zheng; Joan Kapusnik-Uner
Journal:  Ann N Y Acad Sci       Date:  2016-10-17       Impact factor: 5.691

8.  Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

Authors:  David I Quinn; John Nemunaitis; Jyotsna Fuloria; Carolyn D Britten; Nashat Gabrail; Lorrin Yee; Milin Acharya; Kai Chan; Nadine Cohen; Assen Dudov
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic.

Authors:  Petra Langerová; Michal Prokeš; Martin Konvalinka; Jana Fürstová; Karel Urbánek
Journal:  Eur J Pediatr       Date:  2013-01-19       Impact factor: 3.183

10.  Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.

Authors:  Agnes L F Chan; Meng-Ting Wang; Chen-Yi Su; Fu-Hsiung Tsai
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.